- Home
- TLSI vs GRX Comparison
TLSI vs GRX Comparison
Compare TLSI & GRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- GRX
- Stock Information
- Founded
- TLSI 2010
- GRX 2007
- Country
- TLSI United States
- GRX United States
- Employees
- TLSI N/A
- GRX N/A
- Industry
- TLSI Medical Specialities
- GRX Finance/Investors Services
- Sector
- TLSI Health Care
- GRX Finance
- Exchange
- TLSI Nasdaq
- GRX Nasdaq
- Market Cap
- TLSI 124.9M
- GRX 151.1M
- IPO Year
- TLSI N/A
- GRX N/A
- Fundamental
- Price
- TLSI $4.69
- GRX $9.64
- Analyst Decision
- TLSI Strong Buy
- GRX
- Analyst Count
- TLSI 6
- GRX 0
- Target Price
- TLSI $11.75
- GRX N/A
- AVG Volume (30 Days)
- TLSI 36.4K
- GRX 39.7K
- Earning Date
- TLSI 11-14-2024
- GRX 01-01-0001
- Dividend Yield
- TLSI N/A
- GRX 5.98%
- EPS Growth
- TLSI N/A
- GRX N/A
- EPS
- TLSI N/A
- GRX 0.26
- Revenue
- TLSI $26,891,000.00
- GRX N/A
- Revenue This Year
- TLSI $60.96
- GRX N/A
- Revenue Next Year
- TLSI $53.65
- GRX N/A
- P/E Ratio
- TLSI N/A
- GRX $38.50
- Revenue Growth
- TLSI 67.90
- GRX N/A
- 52 Week Low
- TLSI $3.50
- GRX $7.73
- 52 Week High
- TLSI $10.42
- GRX $10.40
- Technical
- Relative Strength Index (RSI)
- TLSI 51.68
- GRX 38.06
- Support Level
- TLSI $4.72
- GRX $9.62
- Resistance Level
- TLSI $5.32
- GRX $9.99
- Average True Range (ATR)
- TLSI 0.31
- GRX 0.19
- MACD
- TLSI 0.01
- GRX 0.02
- Stochastic Oscillator
- TLSI 47.52
- GRX 23.91
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.